Last reviewed · How we verify

Neckshoulderarm syndrome — Treatment Landscape & Competitive Intelligence

Neckshoulderarm syndrome (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Neckshoulderarm syndrome, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Voltaren DICLOFENAC Hisamitsu Pharmaceutical Co., Inc Nonsteroidal Anti-inflammatory Drug Prostaglandin G/H synthase 2 1988-01-01
Arthrotec Diclofenac Sodium Pfizer diclofenac Acid-sensing ion channel 3 1988-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Hisamitsu Pharmaceutical Co., Inc · 1 drug in Neckshoulderarm syndrome
  2. Pfizer · 1 drug in Neckshoulderarm syndrome

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Neckshoulderarm syndrome:

Cite this brief

Drug Landscape (2026). Neckshoulderarm syndrome — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/neckshoulderarm-syndrome. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing